All In Biotech

Drug Trial Radar · NCT06699849

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

A Phase 2, Multicenter, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Jul 10, 2025

Primary completion

Oct 22, 2027

Study completion Oct 22, 2027

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Nov 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to evaluate the safety and tolerability of CSL889 in study participants, and to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD.

Conditions

  • Sickle Cell Disease Vaso-occlusive Crisis

Interventions

  • CSL889Biological

    CSL889 is a solution for infusion to be administered by the IV route.

  • PlaceboDrug

    Volume and regimen matched to CSL889 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to Day 28 (End of study [EOS] Visit)
  2. Percentage of participants with TEAEsTime frame: Up to Day 28 (EOS Visit)
  3. Number of participants with detectable treatment emergent (TE) anti-CSL889 antibodiesTime frame: Up to Day 28 (EOS Visit)
  4. Percentage of participants with detectable TE anti-CSL889 antibodiesTime frame: Up to Day 28 (EOS Visit)
  5. Time to resolution of VOC (time to discontinuation of parenteral opioids)Time frame: Up to Day 28 (EOS Visit)

Locations

30 sites in 3 countries. Site status is shown where the registry gives one.

  • Univ. of California, San Francisco Health Care

    Oakland, California · Recruiting

  • University of California Irvine

    Orange, California · Recruiting

  • Medstar Washington Hospital Center

    Washington D.C., District of Columbia · Recruiting

  • Golisano Children's Hospital

    Fort Myers, Florida · Recruiting

  • The Foundation for Sickle Cell Disease

    Hollywood, Florida · Recruiting

  • Arthur M. Blank Hospital-Children's Healthcare of Atlanta

    Atlanta, Georgia · Recruiting

  • University of Illinois at Chicago

    Chicago, Illinois · Recruiting

  • University of Louisville Hospital

    Louisville, Kentucky · Recruiting

  • University of Maryland

    Baltimore, Maryland · Recruiting

  • Detroit Medical Center

    Detroit, Michigan · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • St. Louis Children's Hospital

    St Louis, Missouri · Recruiting

  • Mount Sinai Medical Center

    New York, New York · Recruiting

  • Jacobi Medical Center

    The Bronx, New York · Recruiting

  • East Carolina University

    Greenville, North Carolina · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • University of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Withdrawn

  • Baskent University School of Medicine

    Adana, Turkey (Türkiye) · Recruiting

  • Hacettepe Universitesi

    Ankara, Turkey (Türkiye) · Recruiting

  • Istanbul Universitesi

    Istanbul, Turkey (Türkiye) · Not yet recruiting

  • Medical Park Mersin Hospital

    Mezitli-Mersin, Turkey (Türkiye) · Recruiting

  • Özel Acibadem Adana Hastanesi

    Seyhan, Turkey (Türkiye) · Recruiting

  • Özel Acibadem Adana Hastanesi

    Seyhan/Adana, Turkey (Türkiye) · Recruiting

  • Mersin Universitesi

    Yenişehir, Turkey (Türkiye) · Recruiting

  • Royal Liverpool University Hospital

    Liverpool, United Kingdom · Recruiting

  • University College London Hospitals NHS Trust

    London, United Kingdom · Recruiting

  • Guy's Hospital

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.